Human cell programming company bit.bio, based in Cambridge, announces a $25 million Series D funding round. The company says the funding is intended to expand its portfolio of human cell models and increase access to its technology for pharmaceutical and biotech firms. The announcement comes about ten months after bit.bio secured its previous investment.

The Next Web and Tech.eu both report the same core details: the round size, the company’s focus on human cell models, and the goal of scaling and broader access. The Next Web adds more specifics about investors involved, stating that existing investor M&G Investments participates and that Dr Jonathan Milner—described as the founder and former CEO of research tools company Abcam—also backs the round. Neither source, based on the provided summaries, gives additional financial terms or discloses a lead investor.